Journal
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Volume 76, Issue 2, Pages 138-145Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FJC.0000000000000854
Keywords
COVID-19; cardiovascular diseases; arrhythmias; atrial fibrillation; cardioversion; pharmacological interactions; experimental therapies; anticoagulant therapy; antiarrhythmic therapy
Ask authors/readers for more resources
Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concerns because of a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known about atrial fibrillation and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in atrial fibrillation management and experimental COVID-19 therapies, based on EU and US summaries of product characteristics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available